Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders-Reference-Cited by-同舟云学术

Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders

Published:2018-02 Issue:2 Volume:17 Page:115-124
ISSN:1568-9972
Container-title:Autoimmunity Reviews
language:en
Short-container-title:Autoimmunity Reviews

Author:

Tudesq Jean-Jacques,Cartron Guillaume,Rivière Sophie,Morquin David,Iordache Laura,Mahr Alfred,Pourcher Valérie,Klouche Kada,Cerutti Diane,Le Quellec Alain,Guilpain Philippe

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference41 articles.

1. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma;Maloney;Blood,1997

2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol Off J Am Soc Clin Oncol,1998

3. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases;Gottenberg;Ann Rheum Dis,2005

4. Rituximab: current status as therapy for malignant and benign hematologic disorders;Abdulla;BioDrugs Clin Immunother Biopharm Gene Ther,2012

5. Action and resistance of monoclonal CD20 antibodies therapy in B-cell non-Hodgkin lymphomas;Pérez-Callejo;Cancer Treat Rev,2015

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study;Virology Journal;2024-09-09

2. Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy;European Journal of Clinical Microbiology & Infectious Diseases;2024-02-15

3. Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA);Rheumatology Advances in Practice;2024

4. Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease;RMD Open;2024-01

5. Association of autoimmune diseases with the occurrence and 28-day mortality of sepsis: an observational and Mendelian randomization study;Critical Care;2023-12-05